Abstract PS5-02-26: A phase I/II, single arm, non-randomized study of ribociclib, a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor inhibitor, in advanced AR-positive triple-negative breast cancer: A Big Ten Cancer Research Consortium Study